Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2022 Financial, Corporate Report By: Investor Brand Network December 14, 2022 at 10:14 AM EST Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has filed its audited financial statements and is reporting on corporate highlights for the fiscal year ending Aug. 31, 2022. Highlights include the World Intellectual Property Organization publishing TRYPF’s international PCT patent application, which covers the intravenous administration of psilocybin and psilocin. The patent is connected to Tryp’s development of TRP-8803, an intravenous infusion of psilocin designed to significantly reduce the time to onset of the psychedelic state, control the depth and duration of the psychedelic experience, and reduce the overall duration of the intervention to a commercially feasible timeframe. Other highlights include the filing of provisional patents for the use of psilocybin for the treatment of patients with binge eating disorder and for the treatment of patients with fibromyalgia. The report also noted the filing of a provisional patent for crystalline forms of TRP-8803. In addition, Tryp started preparations for a phase 2a trial using TRP-8802 to evaluate psilocybin-assisted therapy among patients with fibromyalgia. “Tryp has continued to execute its multipronged strategy of exploring the clinical utility of psilocybin-assisted psychotherapy, expanding its IP portfolio, and advancing TRP-8803 (IV-infused psilocin), the company’s proprietary and eventual commercial product,” said Tryp Therapeutics CEO Jim Gilligan in the press release. “To that end, Tryp expects to have the interim results from our phase 2a clinical binge eating disorder trial as early as January 2023 and has submitted several provisional patents related to fibromyalgia, binge eating disorder, and co-formers of TRP-8803. Furthermore, the company has completed a series of pharmacology and toxicology programs necessary to advance TRP-8803 into the clinic. With a burgeoning pipeline and a variety of novel and impactful provisional patents in place, we look forward to continuing to execute our business plan in 2023 and beyond.” To view the full release, visit https://ibn.fm/rqUez About Tryp Therapeutics Inc. Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) for the potential treatment of eating disorders, chronic pain, and other indications. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.investorwire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.investorwire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2022 Financial, Corporate Report By: Investor Brand Network December 14, 2022 at 10:14 AM EST Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has filed its audited financial statements and is reporting on corporate highlights for the fiscal year ending Aug. 31, 2022. Highlights include the World Intellectual Property Organization publishing TRYPF’s international PCT patent application, which covers the intravenous administration of psilocybin and psilocin. The patent is connected to Tryp’s development of TRP-8803, an intravenous infusion of psilocin designed to significantly reduce the time to onset of the psychedelic state, control the depth and duration of the psychedelic experience, and reduce the overall duration of the intervention to a commercially feasible timeframe. Other highlights include the filing of provisional patents for the use of psilocybin for the treatment of patients with binge eating disorder and for the treatment of patients with fibromyalgia. The report also noted the filing of a provisional patent for crystalline forms of TRP-8803. In addition, Tryp started preparations for a phase 2a trial using TRP-8802 to evaluate psilocybin-assisted therapy among patients with fibromyalgia. “Tryp has continued to execute its multipronged strategy of exploring the clinical utility of psilocybin-assisted psychotherapy, expanding its IP portfolio, and advancing TRP-8803 (IV-infused psilocin), the company’s proprietary and eventual commercial product,” said Tryp Therapeutics CEO Jim Gilligan in the press release. “To that end, Tryp expects to have the interim results from our phase 2a clinical binge eating disorder trial as early as January 2023 and has submitted several provisional patents related to fibromyalgia, binge eating disorder, and co-formers of TRP-8803. Furthermore, the company has completed a series of pharmacology and toxicology programs necessary to advance TRP-8803 into the clinic. With a burgeoning pipeline and a variety of novel and impactful provisional patents in place, we look forward to continuing to execute our business plan in 2023 and beyond.” To view the full release, visit https://ibn.fm/rqUez About Tryp Therapeutics Inc. Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) for the potential treatment of eating disorders, chronic pain, and other indications. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.investorwire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.investorwire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has filed its audited financial statements and is reporting on corporate highlights for the fiscal year ending Aug. 31, 2022. Highlights include the World Intellectual Property Organization publishing TRYPF’s international PCT patent application, which covers the intravenous administration of psilocybin and psilocin. The patent is connected to Tryp’s development of TRP-8803, an intravenous infusion of psilocin designed to significantly reduce the time to onset of the psychedelic state, control the depth and duration of the psychedelic experience, and reduce the overall duration of the intervention to a commercially feasible timeframe. Other highlights include the filing of provisional patents for the use of psilocybin for the treatment of patients with binge eating disorder and for the treatment of patients with fibromyalgia. The report also noted the filing of a provisional patent for crystalline forms of TRP-8803. In addition, Tryp started preparations for a phase 2a trial using TRP-8802 to evaluate psilocybin-assisted therapy among patients with fibromyalgia. “Tryp has continued to execute its multipronged strategy of exploring the clinical utility of psilocybin-assisted psychotherapy, expanding its IP portfolio, and advancing TRP-8803 (IV-infused psilocin), the company’s proprietary and eventual commercial product,” said Tryp Therapeutics CEO Jim Gilligan in the press release. “To that end, Tryp expects to have the interim results from our phase 2a clinical binge eating disorder trial as early as January 2023 and has submitted several provisional patents related to fibromyalgia, binge eating disorder, and co-formers of TRP-8803. Furthermore, the company has completed a series of pharmacology and toxicology programs necessary to advance TRP-8803 into the clinic. With a burgeoning pipeline and a variety of novel and impactful provisional patents in place, we look forward to continuing to execute our business plan in 2023 and beyond.” To view the full release, visit https://ibn.fm/rqUez About Tryp Therapeutics Inc. Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) for the potential treatment of eating disorders, chronic pain, and other indications. The company has an ongoing phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida and an upcoming phase 2a clinical trial with the University of Michigan for the treatment of fibromyalgia, both of which are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Subsequent studies are expected to utilize TRP-8803, which has the potential to further improve efficacy, safety and patient experience. For more information about the company, please visit www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF About InvestorWire InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.investorwire.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer InvestorWire (IW)8033 Sunset Blvd Suite 1037-IWLos Angeles, CA 90046310.299.1717 Officewww.investorwire.comEditor@InvestorWire.com InvestorWire is part of the InvestorBrandNetwork
